# Konfoong Biotech International Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/konfoong-biotech-international-co

- Industry: Biotechnology
- Headquarters: Yuyao, China
- Website: www.kfbiopathology.com
- Total disclosed funding: $29M
- Latest round: Series C (Jul 12, 2022)
- Investors on record: 9

## About

Based in Yuyak, China, and established in 2011, Konfoong Biotech International Co., Ltd., is a bioinformatics company that focuses on the digital pathology fields. In 2014, the company's pathology In 2017, the company obtained a medical device production license and established Hangzhou Artificial Intelligence R&D Center. And then, the company obtained the medical device registration certificate for Cervical Cancer and TB AI Screening System. The company has more than 200 patents, and 7 class level two medical device registration certificates. The company has served more than 2,000 medical institutions, and a total of 50 million slides were scanned.

The company engages in digital pathology slide scanners, telepathology platforms, AI-assisted pathology diagnosis systems, routine pathology equipment, and pathology diagnosis services.

## Funding rounds

- Series C, Jul 12, 2022, $15M — Wisdomont Capital
- Series B, Apr 2, 2020, $14M — Intel Capital, Yinxinggu Capital, Newline Media Capital
- Series A, Nov 1, 2016 — Cowin Capital, Share Capital, Real Power Capital, QF Capital, Pku Capital

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series A
- Real Power Capital (https://capitalatlas.ai/funds/real-power-capital) — Series A
- QF Capital (https://capitalatlas.ai/funds/qf-capital) — Series A
- Pku Capital (https://capitalatlas.ai/funds/pku-capital) — Series A
- Intel Capital (https://capitalatlas.ai/funds/intel-capital) — Series B
- Yinxinggu Capital (https://capitalatlas.ai/funds/yinxinggu-capital) — Series B
- Newline Media Capital — Series B
- Wisdomont Capital (https://capitalatlas.ai/funds/wisdomont-capital) — Series C